Impact of Inflation Reduction Act on Biosimilars

This report discusses the implications of the Inflation Reduction Act (IRA) on the biosimilar marketplace in the United States. It outlines how biosimilars have contributed to significant savings in the healthcare system, amounting to $21 billion over the past six years, and forecasts an additional $180 billion in savings over the next five years. The report emphasizes the competitive dynamics introduced by biosimilars, which have led to decreased average sales prices (ASPs) for both biosimilars and reference biologics. However, it also highlights the potential negative impact of the IRA, which includes provisions for drug price-setting that may discourage the development of new biosimilars. The report details the challenges faced by biosimilar manufacturers, including long development timelines and high costs, which may be exacerbated by the IRA's pricing regulations. It concludes that while the IRA aims to control costs, it may ultimately hinder the growth and investment in the biosimilar market, threatening future savings and competition.